

Thirty Fourth Annual Report

2011

Edited by Stephen McDonald Kylie Hurst

Funded by

Australian Organ and Tissue Authority Kidney Health Australia New Zealand Ministry of Health

Supported by

AMGEN Australia Pty Ltd
Bristol-Myers Squibb
Genzyme Australasia Pty Ltd
Janssen-Cilag Pty Ltd
Pfizer Pty Ltd
Novartis Pharmaceuticals Australia Pty Ltd
Roche Products Pty Ltd

i



Funding

ANZDATA Registry is funded by Australian Organ and Tissue Authority Kidney Health Australia New Zealand Ministry of Health

Supported by unrestricted research Grants from AMGEN Australia Pty Ltd Genzyme Australia Janssen-Cilag Pty Ltd Novartis Pharmaceuticals Australia Pty Ltd Roche Products Pty Ltd Wyeth Australia Pty Ltd

Coordinating Centre

ANZDATA Registry 9th Floor - East Wing Royal Adelaide Hospital North Terrace, Adelaide, South Australia, 5000

Phone (61-8) 8222.0949 Fax (61-8) 8222.0985 / 8222.0995 Email anzdata@anzdata.org.au Webhttp://www.anzdata.org.au

Prof G Russ
A/Prof S McDonald
Dr P Clayton
Mrs. K Hurst
Mr B Livingston
Mrs H Dent
Mrs A Gulvani
Mrs A Gulvani
C ANZDATA Executive
Angen Fellow in Epidemiology
Registry Manager / Editor
Information Manager
Biostatistician
Biostatistician
Biostatistician

Mrs A Gulyani Biostatistician Dr N Briggs Biostatistician

Dr B Grace Research Fellow - ANZDATA Registry

Ms C Leitch Administration
Ms K Textor Administration

Printed in Adelaide, South Australia, 2012

© Copyright 2011 by the ANZDATA Registry

ISSN 1329-2870

Acknowledgments

ANZDATA Registry offers its most grateful appreciation to everyone who helped make this 33rd Annual Report possible, especially the professionals and the staff of all the Renal Units and Tissue Typing Laboratories, upon whose reporting of data this enterprise ultimately depends.

Suggested Citation

An example of suggested citation for this report is as follows:

.. [Author's name] ..
Peritoneal Dialysis .. [page numbers] ..
ANZDATA Registry Report 2010
Australia and New Zealand Dialysis and Transplant Registry Adelaide, South Australia.

Editors: Stephen McDonald, Kylie Hurst

Publications based upon ANZDATA Registry information reported here or supplied upon request, must include the citation as noted above and the following notice:

The data reported here have been supplied by the Australia and New Zealand Dialysis and Transplant Registry. The interpretation and reporting of these data are the responsibility of the Editors

no way should be seen as an official policy or interpretation of the Australia and New Zealand Dialysis and Transplant Registry.

| | | Page | | | Page |
|------------|--|-------|------------|--|-------|
| Contents | | iii | Chapter 6 | Peritoneal Dialysis (Continued) | |
| | Introduction | vi | | Antibiotic Treatment | 6-23 |
| | ANZDATA Committees | vii | | Outcomes | 6-24 |
| | Privacy | viii | | Haemoglobin | 6-26 |
| | Guidelines for Data Release | ix | | Haemoglobin by Treating Centre | 6-27 |
| | Attribution of Publications | Х | | Ferritin and Transferrin Saturation | 6-28 |
| | Contributing Authors | xi | | Ferritin by Treating Centre | 6-29 |
| | Definitions | xii | | Serum Calcium - By Treating Centre | 6-30 |
| | Participating Hospitals | XV | | Serum Phosphate - By Treating Centre | 6-31 |
| | Transplanting Hospitals | xvi | | Calcium-Phosphate - By Treating Centre | 6-32 |
| | Satellite Haemodialysis Units | xii | | . , , | |
| | Publications 2010 | xvii | Chapter 7 | Transplant Waiting List | 7-1 |
| | Data Collection Form | xxi | • | Data from the National Organ Matching Scheme (Australia) an | d |
| | Summary | xxiii | | New Zealand Kidney Allocation Scheme, Stephen McDonald | |
| Chapter 1 | Stock and Flow | 1-1 | Chapter 8 | Transplantation | 8-1 |
| | Blair Grace, Kylie Hurst Stephen McDonald | | - | Philip Clayton, Scott Campbell, Kylie Hurst, | |
| | zian eraee, ryne riaiet etepriori mezeriaia | | | Stephen McDonald, Steven Chadban | |
| Chapter 2 | New Patients | 2-1 | | Transplants Performed in 2010 | 8-2 |
| Gliapto: 2 | Blair Grace, Hannah Dent, Kylie Hurst, Stephen McDonald | | | Transplant Rate of Patients Dialysed | 8-4 |
| | Intake of Patients and Age of New Patients | 2-2 | | Age of Recipients Transplanted in 2010 | 8-5 |
| | State of Origin of New Patients | 2-3 | | Ethnicity of Transplant Recipients | 8-6 |
| | Incidence Rates new RRT by State | 2-3 | | Australian Regional Activity | 8-7 |
| | Incidence Rates new RRT by state | 2-5 | | Living Donor Transplants | 8-8 |
| | Late Referral | 2-6 | | Timing of Live Donor Transplants | 8-11 |
| | Late Referral Related to Treatment | 2-7 | | Functioning Transplants - Operations | 8-12 |
| | Co-morbid Conditions | 2-7 | | Rates of Graft Loss | 8-16 |
| | | | | Immunosuppression | 8-18 |
| | Primary Renal Disease | 2-10 | | Use of Antibody Therapy | 8-20 |
| | Miscellaneous Causes of ESRD | 2-11 | | Rejection Rates | 8-22 |
| | Biopsy of New Patients | 2-12 | | Short Term Primary Deceased Donor Survival | 8-23 |
| | - | | | Long Term Primary Deceased Donor Survival | 8-25 |
| Chapter 3 | Deaths | 3-1 | | Short Term Deceased Second-Subsequent Survival | 8-26 |
| | Stephen McDonald, | | | Long Term Deceased Second-Subsequent Survival | 8-27 |
| | Introduction. | 3-2 | | Short Term Primary Living Donor Survival | 8-28 |
| | Death Rates During Renal Replacement Therapy | 3-3 | | Long Term Primary Living Donor Survival | 8-30 |
| | Dialysis Mortality Rates | 3-4 | | Long Term Living Second-Subsequent Survival | 8-31 |
| | Survival by Age & Comorbidity | 3-4 | | Long Term Living Second-Subsequent Survival | 0-31 |
| | Cause of Deaths | 3-5 | Chapter 9 | Organ Procurement | 9-1 |
| | Deaths from Malignancy | 3-6 | Chapter 3 | Graeme Russ,, Kylie Hurst, Kathy Hee | 3-1 |
| | Deaths Withdrawal-Related to Malignancy | 3-7 | | Glaeine Russ,, Rylle Hurst, Rathy Hee | |
| Chapter 4 | Method and Location of Dialysis Nancy Briggs,Kylie Hurst, Stephen McDonald | 4-1 | Chapter 10 | Cancer Report Angela Webster, Germaine Wong, Patrick J Kelly | 10-1 |
| | Transy Engge, Tylio Transi, Stophion Mozeriala | | | | |
| Chapter 5 | Haemodialysis. | 5-1 | Chapter 11 | Paediatric Report | 11-1 |
| • | Kevan Polkinghorne,, Aarti Gulyani, Hannah Dent, Kylie | | | Steven McTaggart, Hannah Dent, Sean Kennedy, Nancy | |
| | Hurst, Stephen McDonald | | | Briggs, Kylie Hurst, Stephen McDonald | |
| | Stock and Flow | 5-2 | | Incidence and Prevalence 1991-2010 | 11-2 |
| | Blood Flow Rates | 5-6 | | Causes of ESKD in Children and Adolescents | 11-3 |
| | Duration of Dialysis | 5-7 | | Modality of Treatment2005-2010 | 11-4 |
| | Outcome Among Haemodialysis Patients | 5-10 | | Haemoglobin—Urea ratios | 11-5 |
| | Membrane Type and Surface Areas | 5-14 | | Biochemical Outcomes | 11-6 |
| | Anaemia | 5-15 | | Vascular Access | 11-7 |
| | Haemoglobin | 5-16 | | PD Technical Survival | 11-8 |
| | Haemoglobin by Treating Centre | 5-17 | | - 10: 10: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: | |
| | Ferritin and Transferrin Saturation | 5-18 | Ob 40 | End-Stage Kidney Disease Among Indigenous Peoples | 40.4 |
| | Ferritin by Treating Centre | 5-19 | Chapter 12 | of Australia and NZ | 12-1 |
| | Serum Calcium - By Treating Centre | 5-20 | | Stephen McDonald, Kylie Hurst, Matthew Jose | 40.0 |
| | Serum Phosphate By Treating Centre | 5-21 | | Introduction and New Patients | 12-2 |
| | Calcium-Phosphate - By Treating Centre | 5-22 | | Incidence Rate | 12-3- |
| | Urea Reduction Ratio | 5-23 | | New Transplants 2001-2010 | 12-6 |
| | Urea Reduction Ratio by Treating Centre | 5-24 | | Prevalent Patients 2006-2010 | 12-8 |
| | Vascular Access at First Treatment | 5-25 | | Dialysis Modality | 12-9 |
| | Prevalent Haemodialysis Access | 5-28 | | Est Glomerular Filtration Rate at Treatment Start | 12-10 |
| | Obesity in Incident Haemodialysis Patients | 5-32 | | Incidence and Prevalence by State/Territory | 12-11 |
| | Obesity in Prevalent Haemodialysis Patients | 5-34 | | Geographical Distribution | 12-14 |
| | Home Haemodialysis | 5-36 | | Late Referral | 12-16 |
| | Technique Failure | 5-39 | | Cause of Death | 12-17 |
| | | | APPENDIX I | (On CD) (and website www.anzdata.org.au) | |
| Chapter 6 | Peritoneal Dialysis | 6-1 | | Stock and Flow Australia and New Zealand | 3-5 |
| | Fiona Brown, Stephen McDonald, Hannah Dent, | | | Numbers and Age Specific Rates - Australia and NZ | 6-25 |
| | Aarti Gulyani, Kylie Hurst | | | Age and Donor Source of New Transplants1963-2010 | 26-27 |
| | Stock and Flow | 6-2 | | Transplanting Hospital and Donor Source1996-2010 | 28-29 |
| | Peritoneal Dialysis Fluids | 6-8 | | Country of Birth of Patients | 30 |
| | Outcome Among Peritoneal Dialysis Patients | 6-11 | | Ethnicity of Patients | 31 |
| | Peritoneal Dialysis Technique Survival | 6-15 | | Australia - Summary 2010 | 32-33 |
| | Technique Failure | 6-17 | | Population by Age - Australia 2002-2010 | 34-35 |
| | Peritonitis | 6-18 | | Location of Dialysis Treatment | 36-40 |
| | Australian Peritonitis Registry | 6-21 | | | 41-42 |
| | | | | New Zealand - Summary 2010 - Population 20012010 | 41-42 |



APPENDIX II - AUSTRALIA (Available on CD and from website www.anzdata.org.au)

CONTENTS

| CONTENTS | |
|--|--|
| Number of New Patients in each Australian State - 1963-2010 Number of New Patients by Age Group - 1963-2010 Number of New Patients in Each Age Group by Gender - Australian States 2005-2010 Number of New Patients by Racial Origin - Australian States 2007-2010 Primary Renal Disease and Age of New Patients - 2006-20010 Primary Renal Disease and Age of New Patients - Australian States 2009-2010 Primary Renal Disease of New Patients - Australian States 2009-2010 Primary Renal Disease of New Patients - Australia and New Zealand - 1997-2010 Primary Renal Disease of New Patients - Australian States 1997-2010 Incident Indigenous/Non Indigenous Patients - Australia and Australian States 1998-2010 Incident Indigenous/Non Indigenous Incident Patients by Age Group - Australian States 2005-2010 DIALYSIS | PAGE 3 4 5-6 7 8 9-11 12 12-13 14-16 17-18 |
| Age and Treatment of Dialysis Patients - 2005-2010 Age and Treatment of Dialysis Patients by Gender - 2008-2010 Age and Treatment of Indigenous / Non Indigenous Patients - 2005-2010 Age and Treatment of Indigenous / Non Indigenous Patients - Australian States - 2005-2010 Race, Primary Renal Disease and Age of Dialysis Patients - Australia 2010 Race, Primary Renal Disease and Age of Dialysis Patients - Australian States 2010 | 19 20 21-22 23-37 38 39-44 |
| Functioning Transplants - By Country of Transplant - 31st December 2007-2010 Functioning Transplants - Transplanting Australian States - 31st December 2009-2010 Gender, Race and Age of Functioning Transplants - Resident Australian States 2010 Gender, Race and Age of Functioning Transplants - Resident Country - 2008-2010 Gender and Race of Functioning Transplants - Resident Australian States 2008-2010 Functioning Australian Transplants by Race, Primary Renal Disease and Age - 31st December 2010 Recipient Donor Source and Age for Transplant Operations 2006-2010 Recipient Donor Source and Age for Transplant Operations by State - 2009-2010 Recipient Gender, Donor Source and Recipient Age for Transplant Operations 2005-2010 Donor Source for Transplant Operations - Australian Referring States 1996-2010 Racial Origin and Primary Renal Disease of New Transplanted Patients - 1997-2010 Cause of Graft Loss - 1999-2009 Year of Graft Loss due to Death or Failure 2000-2010 Year of Graft Loss due to Death or Failure - Age Related - 2000-2010 | 45 46-47 48-49 50 51 52 53 54 55 56 57 58 59 |
| DEATHS Death and Mode of Treatment - 2005-2010 Death and Mode of Treatment - Australian States 2010 Cause of Deaths - Haemodialysis and Peritoneal Dialysis 2010 Cause of Deaths - Peritoneal Dialysis (continued) and Transplant 2010 Site and Type of Infection Causing Death - 2010 Cause of all Deaths by Gender and Race - Female -2010 Cause of all Deaths by Gender and Race - Male - 2010 Cause of Dialysis Deaths - Australian States - 1996-2010 Cause of Transplant Deaths - Australian States - 1996-2010 Cause of Deaths by Racial Origin - Dialysis and Transplant - Australia 1997-2010 Treatment Withdrawal Related to Treatment Mode, Disease, Gender and Age - 2008-2010 | 60 61 62 63 64-65 66 67 68 69 70 71 |
| CoMorbid Conditions at Entry - 2010 CoMorbid Conditions at Entry - 2010 CoMorbid Conditions at Entry - Non Diabetic Primary Renal Disease Patients - 2006-2010 CoMorbid Conditions at Entry - Diabetic Primary Renal Disease Patients - 2006-2010 Race and Age of New CoMorbid Diabetic / Non Diabetic Patients - Australia-2010 Race of New CoMorbid Diabetic / Non Diabetic Patients - Australia 1999-2010 CoMorbid Conditions at Entry - All Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Caucasoid Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Aboriginal/Torres St Islanders - Each Year - 1999-2010 CoMorbid Conditions at Entry - Asian Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Haemodialysis and Peritoneal Dialysis as First Treatment 2010 | 72 73 74 75 76 77 78 79 80 81 82-83 |
| PATIENT DATA - TRANSPLANT AND DIALYSIS AS AT 31st December 2009 Currently Functioning Transplant - Transplant Functioning Australia and New Zealand >26 years Currently Functioning Transplant - Third, Fourth, Fifth Graft - Australia and New Zealand Currently Functioning Non Related Live Donor Transplant for >11 years - Australia and New Zealand Uninterrupted Dialysis for >15 years - Australia and New Zealand - December 2010 Longest Surviving Patients >30 years (Previously transplanted) Dialysis Dependent December 2010 | 84-87 88-89 90 91 92 |
| Haemodialysis Analysis Related to Age Groups Haemodialysis End of Survey, Transplant or Death Dec 2010 - Dec 2009 - Dec 2008 - Dec 20067 | 93-94 |
| IMMUNOSUPPRESSION Immunosuppressive Therapy at Specific Intervals - Australian Grafts 1998-2010 | 95-97 |

APPENDIX III - NEW ZEALAND (Available on CD and from website www.anzdata.org.au)

CONTENTS

| | PAGE |
|--|--|
| New Patients Number of New Patients in each Age Group - 1965-2010 Number of New Patients by Racial Origin - 2006-2010 Primary Renal Disease of New Patients - 2005-2010 Gender, Primary Renal Disease and Age of New Patients - 2008-2010 Racial Origin and Primary Renal Disease of New Patients - 1998-2010 | 4 5 6 7 8 |
| DIALYSIS Age and Treatment of Dialysis Patients - 2005-2010 Gender, Treatment and Age of Dialysis Patients - 2008-2010 Racial Origin, Primary Renal Disease and Age of Dialysis Patients - 31st December 2010 | 9 10 11 |
| TRANSPLANTATION Functioning Transplants - By Country of Transplant - 31st December 2007-2010 Gender, Racial Origin and Age of Functioning Transplants - Resident Country - 2008-2010 Functioning Transplants by Racial Origin, Primary Renal Disease and Age - 31st December 2010 Donor Source and Recipient Age for Transplant Operations - 2006-2010 Racial Origin and Primary Renal Disease of New Transplanted Patients by Year - 1997-2010 Recipient Gender, Donor Source and Recipient Age - Transplant Operations 2005-2010 Cause of Graft Loss - 2000-2010 Year of Graft Loss due to Death or Failure - Age Related - 2000-2010 | 12 13 14 15 16 17 18 18 |
| DEATHS Death and Mode of Treatment - 2005-2010 Cause of Deaths - Haemodialysis, Peritoneal Dialysis and Transplant - 2010 Site and Type of Infection Causing Death - 2010 Cause of all Deaths by Gender, Racial Origin and Age - Female -2010 Cause of all Deaths by Gender, Racial Origin and Age - Male - 2010 Cause of Dialysis Death by Gender and Racial Origin - 1998-2010 Cause of Transplant Death by Gender and Racial Origin - 1998-2010 Treatment Withdrawal Related to Treatment Mode, Disease, Gender and Age - 2008-2010 | 20 21 22 23 24 25 26 27 |
| CoMorbid Factors at Entry - 2010 CoMorbid Conditions at Entry - 2010 Racial Origin and Age of New CoMorbid Diabetic / Non Diabetic Patients - 2010 CoMorbid Conditions at Entry - Non Diabetic Primary Renal Disease Patients - 2006-2010 CoMorbid Conditions at Entry - Diabetic Primary Renal Disease Patients - 2006-2010 Racial Origin of CoMorbid Diabetic/Non Diabetic Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - All Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Caucasoid Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Maori Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Pacific People Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Pacific People Patients - Each Year - 1999-2010 CoMorbid Conditions at Entry - Peritoneal Dialysis as First Treatment 2010 | 28 29 29 30 31 32 33 34 35 36 37 38 |
| PATIENT DATA - TRANSPLANT AND DIALYSIS AS AT 31ST DECEMBER 2009 Currently Functioning Transplant - Transplant Functioning >24 years Uninterrupted Dialysis for >11 years Longest Surviving Patients >19 years (Previously transplanted) Dialysis Dependent December 2009 | 39 40 41 |
| HAEMODIALYSIS ANALYSIS RELATED TO AGE GROUPS Haemodialysis End of Survey, Transplant or Death Dec-2010 - Dec 2009 - Dec 2008 - Dec 2007 Number of Treatments Per Week Blood Flow Rate (mls/ min) Hours of Treatment Per Week | 42-43 |
| IMMUNOSUPPRESSION Immunosuppressive Therapy at Specific Intervals - New Zealand Graft 1998-2010 | 44 |



The ANZDATA Registry has great pleasure in presenting its 2011 annual report. This is the 34th annual report from the Registry and covers data collected until the 31st of December 2010.

The Registry acknowledges that the report is a tribute to the commitment and involvement of renal units throughout Australia and New Zealand. This commitment results in an enormous amount of time and work from staff of these units. It has ensured 100% of units in Australia and New Zealand participate and we continue to be confident that all the patients who have received chronic dialysis and transplantation treatments in Australia and New Zealand in this time period are included.

2011 has been a year of significant change in the staffing of the Registry office. After 34 years as Manager of the Registry, Lee Excell retired from that role in December 2010. We are pleased that she has continued in a part time advisory role in 2011 to assist in the transition to new management.

In May 2011, Ms Kylie Hurst was appointed as the new Manager of ANZDATA. Kylie brings to the Registry a wealth of experience in data management in her previous role at the Princess Alexandra Hospital. Her prior knowledge of and experience with ANZDATA in that role has proven to be invaluable in starting her new role.

Brian Livingston has continued as information manager in 2011 and Christina Leitch continues to provide administrative support. Bio-statistical expertise has been provided by Hannah Dent and Nancy Briggs.

Associate Professor Stephen McDonald continues in his role as Executive Officer of the Registry. His intellectual and academic leadership of the Registry has been inspirational and has maximized the dissemination of the data and its analysis both nationally and internationally.

Dr Philip Clayton continues as Amgen Fellow in Epidemiology. Since his appointment to this position in 2010, he has been involved in a number of research projects utilizing the database and has published and presented the results nationally and internationally. He has demonstrated excellent analytical skills and scientific rigor. We are greatly indebted to Amgen who continue to make a commitment to the funding of this position which has proven to be a major stimulus for the academic output of the Registry. Dr Blair Grace has also been active in analysis of the ANZDATA database as part of a collaborative NH&MRC funded project, supervised by A/ Prof McDonald.

The ANZDATA Registry Steering Committee has once again been chaired by Professor Steven Chadban. We thank Steven for his inspired leadership and his ongoing interest in the Registry and its operations and output. Once again involvement of many individuals who have been members of the ANZDATA registry committees and working groups is gratefully acknowledged. The members of these groups are listed on page vii of this report.

Major funding for the Registry has been provided from the Australian Commonwealth Department of Health and Ageing through the Australian Organ and Tissue Donation and Transplant Authority, Kidney Health Australia and the New Zealand Ministry of Health.

We are also grateful to industry for support. In 2011, non-tied grants have been received from Baxter, Genzyme, Novartis and Roche.

Graeme Russ

Chair ANZDATA Executive
December 2011

ANZDATA REGISTRY EXECUTIVE COMMITTEE

Professor Graeme Russ—Chair A/Professor Stephen McDonald—Executive Officer Mrs Kylie Hurst—Registry Manager

ANZDATA REGISTRY STEERING COMMITTEE (2010 MEMBERS)

Professor Steven Chadban—Chair

Professor Graeme Russ

A/Professor Stephen McDonald

Mrs Kylie Hurst

Dr Phillip Clayton (Fellow in Epidemiology)

Dr Fiona Brown (Project Manager—Peritoneal Dialysis)

Dr Scott Campbell (Project Manager—Transplantation)

Dr Matthew Jose (IProject Manager—Indigenous Interest Group)

Dr Wai Lim

Dr Grant Pidgeon (New Zealand Representative)

Dr Helen Pilmore

Dr Nic Gray

A/Professor Robyn Langham

Dr Timothy Mathew (Kidney Health Australia Representative)

Dr Sean Kennedy (Project Manager—Paediatric Group)

A/Professor Kevan Polkinghorne (Project Manager—Haemodialysis)

Dr Angela Webster (Project Manager—Cancer)

Dr Germaine Wong (Fellow in Cancer Epidemiology)

Mr Damian Harding (Consumer Representative)

Ms Cathy Hill (Nursing Representative)

ANZDATA REGISTRY WORKING GROUPS (2010 MEMBERSHIP)

Transplant Working Group

Dr Scott Campbell (Project Manager) A/Professor Stephen McDonald Professor Graeme Russ Professor Steven Chadban Dr Wai Lim

Cancer Working Group

Dr Angela Webster (Project Manager)
Dr Germaine Wong (Fellow in Cancer Epidemiology)
A/Professor Stephen McDonald
Professor Randall Faull
Professor Adrian Hibberd
Dr Rob Carroll

Peritoneal Dialysis Working Work

Dr Fiona Brown (Project Manager) Professor David Johnson A/Professor Stephen McDonald A/Professor Kym Bannister Dr Kate Wiggins

Paediatric Working Group

Dr Steven McTaggart (Project Manager) A/Professor Stephen McDonald Dr Paul Henning Dr Lily Johnstone

Haemodialysis Working Group

A/Professor Kevan Polkinghorne (Project Manager) A/Professor Stephen McDonald Professor Richard Allan A/Prof Rowan Walker Dr Mark Marshall Dr Vincent Lee

Indigenous Interest Group

Dr Matthew Jose (Project Manager) A/Professor Stephen McDonald A/Professor Mark Thomas Ms Gillian Gorham Professor John Collins Dr Natasha Rogers Dr Jacqueline Hughes Ms Lesley Salem



PRIVACY

In December 2001 changes to the Commonwealth Privacy Act were introduced which have led to changes to the collection of personal information. Essentially these extend to the private sector a number of changes based around 10 "National Privacy Principles" (NPP's). A detailed exposition of these can be found at the Privacy Commissioner's website (www.privacy.gov.au). Briefly, however, health information is treated as "sensitive" information, which must usually be collected and handled with consent of the person, unless certain conditions are met. Patients are entitled to view the information the Registry holds about them, and request alterations if the data is thought to be inaccurate.

Each Australian State has also enacted similar provisions which cover practice and patients in public hospitals.

ANZDATA does not release data identifiable by patient name. Results are published/released in tabular or graphic format only. Requests for data are met using deindentified data only. On occasion, when data identifying particular hospitals is involved, consent from the Director of the relevent renal unit is sought prior to the release of information.

COLLECTION OF DATA

ANZDATA spent some time during 2002 formulating an appropriate response to these issues including seeking advice from a variety of sources. The approach taken has been that of a "opt-out" consent, whereby patients are distributed information outlining the nature and purpose of the information collected, offered an opportunity to view that data and ask questions, and the opportunity to request withdrawal of part or all of their data. This approach is explicitly suggested for Registries by the Privacy Commissioner in his "Guidelines for the Health Sector". To this end ANZDATA has circulated to all participating hospitals a patient information sheet (see opposite), for each hospital to use (or a locally modified version if appropriate) to inform patients.

At the time of data collection each unit is asked to certify that they have complied with measures under the relevant privacy measures.

Tissue Typing Data and Transplant Waiting List data are collected in each Tissue Typing Laboratory and entered into the National Organ Matching System database. These data are transmitted to ANZDATA for inclusion in the ANZDATA database and for this Report.

ANZDATA REGISTRY

AUSTRALIA AND NEW ZEALAND DIALYSIS AND TRANSPLANT REGISTRY

C/- Royal Adelaide Hospital North Terrace, Adelaide, 5000 South Australia Phone: (08) 8222.0949 Fax: (08) 8222.0985 Email: anzdata@anzdata.org.au Web: http://www.anzdata.org.au

Important Privacy Information

As part of routine medical care of people receiving treatment with dialysis or kidney transplantation, your kidney specialist collects certain information about the patients they treat. All kidney specialists throughout Australia and New Zealand report this information every twelve months to the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). ANZDATA collects the information for the purpose of monitoring treatments and performing analyses to improve quality of care for people with kidney failure.

1. What is ANZDATA?

ANZDATA is an organization set up by Kidney Health Australia and the Australia and New Zealand Society of Nephrology to monitor dialysis and transplant treatments. ANZDATA is funded by the Australian and New Zealand Governments and Kidney Health Australia.

2. What information is collected about you?

This information includes your name, age, gender, racial origin, hospital of treatment, some aspects of your medical condition (such as whether you have diabetes) and details about the type of kidney treatment you are receiving (dialysis or transplant).

We **<u>DO NOT</u>** collect details about your address, telephone number, medical insurance, or non-medical matters such as occupation, income, etc.

3. Is personal data ever released?

The identity of people in the database <u>IS NOT released publicly nor in any reports</u>. Measures have been put into place to ensure the security of all collected information.

4. What is this information used for ?

The information is used primarily for quality assurance, investigating patterns of kidney disease, and planning appropriate health services. We release reports on a variety of topics, including an Annual Report examining the rates and treatment of kidney failure in Australia and New Zealand. We also have a major role in ensuring the quality of patient care by sending to each kidney unit each year a report outlining their activity. These reports also compare the outcome of the treatment they provide with that of other units throughout the two countries.

Reports are also produced at a state and national level, and from time to time analyses are also produced for renal units, government health departments and industry concentrating on particular aspects of renal failure management e.g. peritoneal dialysis, transplantation, haemodialysis.

5. Can you see what personal information ANZDATA collects and the reports that it produces ?

Individuals are able to view their own information on request. You can request alterations if you believe it is inaccurate. You may also opt not to have your treatment included in this database, and you should let your kidney specialist know if this is the case. You can also choose not to have some information (eg racial origin) recorded. However, if your information is not included in the Registry, the ability to compare results in Australia and New Zealand or to analyse the results of different treatment methods and for different patient types (eg diabetics) will be compromised.

The national reports and much other material produced by ANZDATA are available free on the Internet at www.anzdata.org.au, or they can be sent to you on request to the address above. Your kidney specialist will also have copies of many of the reports.

If you wish to discuss any of the issues raised here, please let your doctor know or telephone the ANZDATA

Registry direct on [08] 8222 0949. You may also write to us (ANZDATA Registry, C/- Royal Adelaide Hospital, DX800, Mail Point 117, North Terrace, Adelaide, SA. 5000) or send us an e-mail (anzdata@anzdata.org.au).



GUIDELINES FOR DATA RELEASE

The policy for release of data to investigators, renal units and others was revised during 2002 and is summarised on the Website. ANZDATA encourages the analysis, use and citation of its data, and receives many data requests annually which vary in size and complexity. At times these overwhelm the limited resources within the Registry, and must be prioritised. Generally, formal requests for data are preceded by a period of consultation with a member of the Registry staff. Requests are welcome from Renal Physicians, other staff members of Renal Units, Charitable Bodies, Academic Institutions, Government Departments and Industry. Requests dealing with identifiable Hospital data (ie data which identifies outcomes of an individual hospital) will only be fulfilled with the explicit consent of the Heads of the relevant Hospital Units. Individual patient identified data (names) is not released.

ATTRIBUTION OF PUBLICATIONS

The policy on attribution of publications which incorporate ANZDATA sourced data was revised during 2002, following a period of consultation with participating physicians.

Where a member of a participating unit has analysed data provided by ANZDATA and subsequently prepared a manuscript, then "ANZDATA Registry" should be acknowledged as a secondary institution in addition to the author's Hospital or University. This applies whether the primary data analysis is performed by the author or by ANZDATA staff. Where the author is an ANZDATA office holder or staff member then the primary attribution should be "ANZDATA Registry".

Where ANZDATA data is only a minor portion of the work, then it may be more appropriate to acknowledge the source explicitly in the "Acknowledgements" section.

In both cases the disclaimer on page ii of this report should be included.

In all cases the source and treatment of the data should be made clear in the "Methods" section. Preferably the abstract (and keywords if applicable) should also include "ANZDATA" which would allow for searching Registry publications.

CONTRIBUTING AUTHORS

Dr Nancy Briggs

Biostatistician
ANZDATA Registry
Royal Adelaide Hospital, North Terrace,
Adelaide, South Australia, 5000

Dr Fiona Brown

Nephrologist Department of Nephrology Monash Medical Centre Clayton Road, Clayton, Victoria, 3168

Dr Scott Campbell

Nephrologist and Transplant Physician, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, 4102

Professor Steven Chadban

Chair - ANZDATA Registry Nephrologist and Transplant Physician, Royal Prince Alfred Hospital, Missenden Road, Camperdown. New South Wales, 2000

Dr Philip Clayton

Epidemiologist, ANZDATA Registry Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000

Mrs Hannah Dent

Biostatistician ANZDATA Registry Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000

Dr Ian Dittmer

Transplant Physician Auckland Renal Transplant Group Clinical Director Department of Renal Medicine Auckland City Hospital

Dr Blair Grace

ANZDATA Registry - Research Fellow Royal Adelaide Hospital, North Terrace Adelaide, South Australia, 5000

Mrs Aarti Gulyani

Biostatistician ANZDATA Registry Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000

Mrs Kylie Hurst

ANZDATA Registry Manager Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000

Ms Kathy Hee

Manager DonateLife SA 165 Grenfell Street Adelaide, South Australia, 5000

Dr Lilian Johnstone

Paediatric Nephrologist Department of Paediatric Nephrology Monash Children's at Clayton, Southern Health Clayton, Victoria, 3168

Dr Matthew Jose

Nephrologist Department of Nephrology Royal Hobart Hospital Hobart, Tasmania, 7000

Dr Sean Kennedy

Paediatric Nephrologist Nephrology Department Sydney Children's Hospital Randwick, NSW, 2031

Dr Patrick Kelly

Senior Lecturer Biostatistics School of Public Health University of Sydney, NSW, 2006

Associate Professor Stephen McDonald

Executive Officer, ANZDATA
Nephrologist
Royal Adelaide Hospital, North Terrace,
Adelaide, South Australia, 5000

Dr Steven McTaggart

Paediatric Nephrologist Renal Unit Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, 4102

Associate Professor Kevan Polkinghorne

Nephrologist Department of Nephrology Monash Medical Centre Clayton Road, Clayton, Victoria, 3168

Professor Graeme Russ

Chair ANZDATA Executive, Co-Director Renal Unit Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000

Dr Angela Webster

Senior Lecturer (Clinical Epidemiology) / Nephrologist School of Public Health Edward Ford Building A27 University of Sydney, NSW, 2006

Dr Germaine Wong

Fellow in Cancer Epidemiology ANZDATA Registry Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000



A number of definitions given below are used throughout this report unless otherwise stated.

1. Wording

Throughout this report 'treatment' refers to renal replacement therapy, including haemodialysis, peritoneal dialysis and transplantation. In places the word "graft" (or "allograft") is used for kidney transplant.

2. Data collection

ANZDATA collects information from all renal units in Australia and New Zealand. Data collection occurs at two time points. Key events (new patients, deaths, transplants) are notified as they occur, with units requested to send this at least monthly. This can occur either via a web-based interface or paper submission. An extensive cross-sectional survey is then performed twelve monthly (for data to 31st December). Currently this is by a paper-based system, with manual completion of the form and manual data entry. No formal audit mechanism is in place at this stage.

For kidney transplants, HLA matching and panel reactive antibodies are obtained direct from the Tissue Typing laboratories in each State.

Monthly summaries are distributed to the contributing units. Results contained in this (and other reports) are based on a final database locked and prepared after the end of year survey returns are received.

3. Inclusion criteria

Included in the Registry are all patients resident in Australia or New Zealand receiving renal replacement therapy where the intention to treat is long-term, ie medical opinion is that renal function will not recover. Cases of acute renal failure are excluded. People who move overseas permanently are censored at date of last treatment (or departure in the case of transplant recipients).

4. Modality attribution

The initial mode of dialysis is determined at 90 days after first treatment, to allow for early changes and maturation of access. Other transfers (between modalities, or from satellite to hospital haemodialysis etc.) are not analysed if less than 30 days, except for transfers between dialysis centres to which a 60 day rule is applied to allow for holiday movements.

5. Underlying renal disease

This is recorded by the treating hospital according to a modified EDTA coding system (details on back of survey form).

6. Deaths

Death rate is predominantly reported as number of patients died/total number of years of treatment of all patients treated at any time during the year. It is expressed as deaths per 100 patient years (pt yrs) at risk.

7. Comorbid conditions

These are recorded by the treating hospital. No formal definitions are supplied; the treating clinician is asked to record whether the patient has coronary artery disease, chronic lung disease, cerebrovascular disease, peripheral vascular disease or diabetes according to their clinical opinion on a yes / suspected / no basis.

8. Transplant Waiting List

The active transplant waiting list is based on data from the National Organ Matching Scheme (Australia) and New Zealand Kidney Allocation Scheme, ARCBS Tissue Typing Laboratories, cross-checked with ANZDATA. Waiting list analyses are for patients' status at 31st December 2010.

9. Derived measures

9.1 Haemoglobin

Haemoglobin is recorded as the last available measurement before the end of the survey period.

9.2 Erythropoietic agents

Erythropoietin agent use is recorded as "yes" if these agents were used at any time during the survey period.

9.3 Iron studies

Iron studies are requested within the last three months of the survey period.

9.4 Estimated creatinine clearance

Where creatinine clearance is estimated from serum creatinine at entry or post transplantation, the Cockroft-Gault equation is used $^{[1]}$

CICr=(140-age)*weight / (814*Crserum)[*0.85 if female]

The weight term used for this is lean body mass, calculated using the equation LBW=(0.9*[height-152])+(50 if male, 45.5 if female) [2]

9.5 Urea reduction ratio / Kt/V

Results are requested in one of these formats, using the stop flow method on a mid-week dialysis. Single pool Kt/V is collected, along with the method used. For conversion of URR to Kt/V urea the formula used [3] is

Kt/V = 0.023*PRU - 0.284 (note that PRU = percent reduction in urea and not URR).

9.6 Body mass index

Body mass index (BMI) is calculated as weight (kg) (height (m))²

The categories used are: underweight <20 kg/m², normal 20-24.9 kg/m², overweight 25-29.9 kg/m² obese >=30 kg/m²

9.7 Peritoneal dialysis measures

These are the standard measures, often calculated by computerised patient management programs.

9.7.1 Residual renal function

The measure used is the arithmetic mean of urea and creatinine clearance from a 24-hour urine collection and serum creatinine and urea.

9.7.2 Peritoneal equilibration test

The ratio of dialysate to plasma glucose is used, following a 4 hour dwell of a 2 litre 2.5% bag of dialysate, performed within 6 months after initiation of peritoneal dialysis.

10. Rates and Measures

10.1 Incidence rates

Except where otherwise stated, quoted incidence rates are per calendar year, and are expressed per million population.

10.2 Prevalence rates

Except where otherwise specified, prevalence rates are point prevalence rates at 31st December 2010.

10.3 Population denominator

All populations used in this report were stratified by age and sex, except for the South Eastern Region of NSW, where sex -specific data was not readily available.

Australian populations were taken from the Australian Bureau of Statistics (ABS), except for estimates for South Eastern NSW, some of which were taken from the NSW Department of Planning and Infrastructure.

All populations used were for 30 June of each year, except for total New Zealand populations, where data for 31 December were readily available, and all websites were accessed 22-24 November 2011.

Population data for each Australian state and territory came from ABS 3201.0 series (1)

Population data for Indigenous Australians were taken from ABS 3238.0 ⁽²⁾, using series A (the most conservative estimates) for populations after 2006.

Populations serviced by the Greater Southern Area Health Service were estimated by the South Eastern Region of NSW. For 2006 onwards, these estimates were taken from the ⁽³⁾ and 2005 estimates were taken from ABS 3235.0 ⁽⁴⁾

All New Zealand population estimates were taken from Statistics New Zealand (SNZ). Total populations were taken from ⁽⁵⁾ and Maori populations were taken from ⁽⁶⁾

Estimates of resident Pacific People populations after were taken from ⁽⁷⁾ for years 2006 onwards. Prior to this, populations of Pacific people before 2006 were only available for years 1996, 2001 (and 2006), and we used linear interpolation to estimate populations for each age and sex group for the years 1997-200 and 2002-2005.

10.4 Survival rates

For transplant recipients, survival rates exclude those who were transplanted overseas or were recipients of multiple organ grafts.

Graft survival (unless otherwise qualified) includes both cessation of graft function (ie return to dialysis) and patient death

Rates for patient survival for fixed periods for transplantation are calculated according to the life-table method and thus include an adjustment to the risk-set of ½ of those censored without failure over the interval to create an "average" risk set

10.5 Graft survival

For outcomes of kidney transplants, graft failure includes both loss of graft function (ie return to dialysis) and death of patients (with graft function). Calculations of patient survival for transplant recipients includes all subsequent modalities (i.e. deaths after graft failure are included). Patients transplanted overseas are excluded from calculations.

10.6 Dialysis Survival

Patient and technique survivals for haemodialysis and peritoneal dialysis are based on the dialysis modality at 90 days after first treatment for patients not transplanted during that period. Patients are followed up until they are either transplanted (at which point they are censored) or until they have a 'permanent' change of dialysis modality or until death or most recent follow up date. A 'permanent' change of dialysis is defined as any change in excess of 30 days.

Peritonitis survivals are calculated from first peritoneal dialysis (ignoring all earlier treatments) to date of first peritonitis episode. If there were no episodes of peritonitis then calculation is censored at change of treatment from peritoneal dialysis to haemodialysis or transplantation. Peritoneal dialysis includes automated peritoneal and continous ambulatory peritoneal dialysis. Excluded are patients who had peritonitis before commencing peritoneal dialysis.

10.8 Death and other event rates

Rates are expressed per 100 person years at risk (unless otherwise stated). Some analyses include survival of all patients, others exclude the first 90 days of followup. This is stated in the individual analyses.



10.9 Age standardisation

All rates are crude, not age-standardised. The age distribution of the populations for Australia and New Zealand are given in Appendix I.

10.10 Peritonitis rates

Peritonitis rates are present using episodes of peritonitis reported during periods of peritoneal dialysis - episodes reported prior to commencement of peritoneal dialysis (for example between Tenckhoff catheter insertion and commencement of peritoneal dialysis) are not included in these calculations.

11. Database

Data is stored on a relational database using ORACLE version 9I.

12. Statistics

Statistical analyses were performed using STATA version 11.

13. References

- 1) Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16;31-41.
- 2) Zasadny KR, Wahl RL: Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variation with body weight and method for correction. Radiology 1993: 189;847-850.
- 1) Basile C, Casino F, Lopez T: Percent reduction in blood urea concentration during dialysis estimates Kt/V in a simple and accurate way. Am J Kidney Dis 1990: 15;40-45.
- 2) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3201.0Jun%202010?OpenDocument
- 3) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3238.01991%20to%202021?OpenDocument
- http://www.planning.nsw.gov.au/population/pdfs/ nsw_state_regional_population_projections_2006_2036_2008release.xls
- 5) http://www.abs.gov.au/AUSSTATS/subscriber.nsf/log?penagent&32350ds0002_nsw_2005_2010.xls&3235.0&Data Cubes&161D786354496224CA2578E10013A0BB&0&2010&04.08.2011&Latest
- 6) http://www.stats.govt.nz/~/media/Statistics/browse-categories/population/estimates-projections/national-pop-estimates-myE31Dec9110FINAL.xls
- 7) http://www.stats.govt.nz/~/media/Statistics/browse-categories/population/estimates-projections/national-pop-estimates/Maori-population-estimates-30-June-19912011.xls
- 8) http://wdmzpub01.stats.govt.nz/wds/TableViewer/tableView.aspx
- 9) Australian Bureau of Statistics: Experimental Projections of the Aboriginal and Torres Strait Islander Population. Canberra, ABS Cat. No. 3101.0, 2002.

Parent hospitals are listed below. In some cases, these have combined as part of a regional network and this is also indicated. The definition of a 'parent hospital' is a pragmatic one, and refers to units which offer a full range of dialysis services (i.e. can commence patients on dialysis, have on-site nephrologist presence and can deal with patients of all degrees of complexity).

In contrast, satellite units (see Page xvii) provide haemodialysis treatments to selected patients, usually with lower staff ratios and no on-site nephrologist.

QUEENSLAND

Allamanda Private Hospital (Fresenius) **Bundaberg Base Hospital**

Cairns Base Hospital

Chermside Dialysis Unit (Fresenius)

Child and Adolescent Renal Service

Goldcoast Hospital

Henry Dalziel Dialysis Centre (Greenslopes) (Baxter)

Hervey Bay Hospital

John Flynn Hospital

Mackay Base Hospital

Princess Alexandra Hospital

Queensland Renal Transplant Service

Rockhampton Base Hospital

Royal Brisbane Hospital

St Andrew's Dialysis Clinic (Diaverum)

Sunshine Coast Health District

Caloundra Private Hospital

Nambour General Hospital

Nambour Selangor Private Hospital

The Townsville Hospital

Toowoomba Hospital

Wesley Private Hospital

NEW SOUTH WALES

Coffs Harbour Hospital **Dubbo Base Hospital**

East Coast Renal Service

Prince of Wales Hospital

St. George Hospital

St. Vincent's Hospital

Sydney Children's Hospital

Wollongong Hospital

Gosford Hospital

John Hunter Hospital

Lismore Hospital

Lismore Private Dialysis Clinic

Macleay Dialysis Centre - Kempsey

Manning Rural Referral Hospital

Mater Misericordiae Hospital

Mavo Private - Taree

Port Macquarie Base Hospital

Port Macquarie Private Hospital

Royal North Shore Hospital

South West Sydney Renal Services

Liverpool Hospital

Statewide Renal Services

Concord Hospital

Royal Prince Alfred Hospital

Sydney Adventist Hospital

Tamworth Hospital

The Children's Hospital at Westmead

The Tweed Hospital

Western Renal Network

Nepean Hospital

Orange Hospital

Westmead Hospital

AUSTRALIAN CAPITAL TERRITORY (ACT)

The Canberra Hospital

VICTORIA

Alfred Hospital

Austin Health

Eastern Health Integrated Renal Services

Epworth Hospital

Forest Hill Dialysis Centre (Fresenius)

Geelong Hospital

Kew Private Dialysis Centre

Malvern Dialysis Centre (Fresenius) Monash Medical Centre - Adult

Monash Medical Centre - Paediatric

North West Dialysis Service

Royal Melbourne Hospital

Royal Children's Hospital

St. Vincent's Hospital

Western Health

ΤΔςΜΔΝΙΔ

Launceston General Hospital Royal Hobart Hospital

SOUTH AUSTRALIA

Flinders Medical Centre

The Queen Elizabeth Hospital

Royal Adelaide Hospital

Women's and Children's Hospital

NORTHERN TERRITORY

Alice Springs Hospital Royal Darwin Hospital

WESTERN AUSTRALIA

Fremantle Hospital

Hollywood Private Hospital

Princess Margaret Hospital for Children

Royal Perth Hospital

Sir Charles Gairdner Hospital

St. John of God Private Hospital

NEW **Z**EALAND

Auckland City Hospital

Starship Children's Hospital

Christchurch Hospital

Dunedin Hospital

Hawkes Bay Hospital

Middlemore Hospital

Palmerston North Hospital

Taranaki Base Hospital

Waikato Hospital Wellington Hospital

Whangarei Area Hospital



QUEENSLAND

Queensland Renal Transplantation Service Princess Alexandra Hospital (Adult and Paediatric) Director of Transplantation - Dr Tony Griffin Ipswich Road Woolloongabba 4102

NEW SOUTH WALES

John Hunter Hospital Director of Transplantation - Professor Adrian Hibberd Lookout Road New Lambton Heights Newcastle 2304

Prince of Wales Hospital Director - Professor Bruce Pussell Barker Street Randwick 2031

Royal North Shore Hospital Director - Dr Bruce Cooper Pacific Highway St Leonards 2065

Statewide Renal Services (Royal Prince Alfred Hospital) Director of Transplantation - Professor Steven Chadban Missenden Road Camperdown 2050

Sydney Children's Hospital Director - Dr Andrew Rosenberg C/- Department of Nephrology Prince of Wales Hospital Barker Street Randwick 2031

The Children's Hospital at Westmead Director - Dr Stephen Alexander Cnr Hawkesbury and Hainsworth Street Westmead 2145

Westmead Hospital Director - Professor Jeremy Chapman Cnr Hawkesbury and Darcy Road Westmead 2145

VICTORIA

Alfred Hospital Director - Professor Napier Thomson Commercial Road Prahran 3181

Austin Health Director - Dr David Power Burgundy Road Heidelberg 3084

Monash Medical Centre (Paediatric) Director - Dr Amanda Walker 246 Clayton Road Clayton 3165

Monash Medical Centre (Adult) Director - Professor Peter Kerr 246 Clayton Road Clayton 3165

Royal Children's Hospital Director - Dr Colin Jones Flemington Road Parkville 3052

VICTORIA (CONTINUED)

Royal Melbourne Hospital Director - Professor Gavin Becker Parkville 3052

St. Vincent's Hospital Director - Professor Robyn Langham 41 Victoria Parade Fitzroy 3065

SOUTH AUSTRALIA

Central Northern Adelaide Transplant Service (from Jan 1, 2010)
Royal Adelaide Hospital
Director - Professor Graeme Russ
North Terrace
Adelaide 5000

(formerly) - The Queen Elizabeth Hospital Woodville, South Australia 5011

Women's and Children's Hospital Director - Dr Paul Henning 72 King William Road North Adelaide 5006

WESTERN AUSTRALIA

Princess Margaret Hospital for Children Director - Dr Ian Hewitt Roberts Road Subiaco 6008

Royal Perth Hospital Director - Dr Kevin Warr Wellington Street Perth 6001

Sir Charles Gairdner Hospital Director - Dr Harry Moody Verdun Street Nedlands 6009

NEW ZEALAND

Auckland City Hospital Director - Dr Ian Dittmer Park Road Grafton, Auckland

Christchurch Hospital Director - Dr David McGregor Riccarton Avenue Christchurch

Starship Children's Hospital Director - Dr William Wong Park Road Grafton, Auckland

Wellington Hospital Director - Dr Grant Pidgeon Riddiford Street Newtown, Wellington South

QUEENSLAND

Atherton Private Hospital - Cairns Base Hospital Cairns Home Training Unit - Cairns Base Hospital Cairns Private Hospital Satellite - Cairns Base Hospital Cooktown Satellite - Cairns Base Hospital

Cooktown Satellite - Cairns Base Hospital
East Street Self Care Dialysis Unit - Rockhampton Hospital
Gympie Satellite - Sunshine Coast Health District
Home Hill Satellite - Townsville Hospital
Innisfail Hospital - Cairns Base Hospital
Ipswich Satellite - Princess Alexandra Hospital
Ipswich Satellite - Townowomba Hospital
Logan Satellite - Princess Alexandra Hospital
Mossman Satellite - Cairns Base Hospital
Mt. Isa Satellite - Townsville Hospital
Noosa Satellite - Sunshine Coast Health District
North Lakes Dialysis Unit - Royal Brisbane Hospital
North Ward Satellite - Townsville Hospital
Palm Island Satellite - Townsville Hospital
Redcliffe Satellite - Princess Alexandra Hospital
Redclands Satellite - Princess Alexandra Hospital
St Vincent's Robina Satellite - Goldcoast Hospital

St Vincent's Robina Satellite - Goldcoast Hospital

NEW SOUTH WALES

Armidale Hospital -Tamworth Hospital Auburn Satellite - Westmead Hospital Ballina Hospital - Lismore Hospital

Bankstown Hospital - South West Sydney Renal Services Bathurst Satellite Dialysis Centre - Orange Hospital Bega Satellite - Statewide Renal Services

Bega Satellite - Statewide Renal Services
Blacktown Regional Dialysis - Westmead Hospital
Bondi Dialysis Unit (Diaverum)
Brewarrina Hospital
Broken Hill Hospital
Campbelltown Satellite - South West Sydney Renal Services

Campbelltown Satellite - South West Sydney Renal Services
Coonamble Hospital
Dame Eadith Walker - Statewide Renal Services
Eora Satellite - Prince of Wales Hospital
Fairfield Satellite - South West Sydney Renal Services
Forbes Hospital - New South Wales
Gosford Satellite - Gosford Hospital
Goulburn Satellite (Fresenius) - Statewide Renal Services
Grafton Hospital - Lismore Hospital
Griffith Base Hospital - Statewide Renal Services
Invarell Satellite - Tamworth Hospital
Lakehaven Satellite - Gosford Hospital
Lanceley Cottage - Royal North Shore Hospital
Lindfield Dialysis Unit (Diaverum)
Liverpool Community Centre - South West Sydney Renal Services
Maitland Hospital - Hunter New England Health
Mona Vale Satellite - Royal North Shore Hospital
Moree Satellite - Tamworth Hospital
Morey Satellite (Fresenius) - Statewide Renal Services
Muswellbrook - Hunter New England Health
Norfolk Island Hospital - Statewide Renal Services
Penrith Community Dialysis Centre - Nepean Hospital Norlick Island Hospital - Statewide Renal Services
Penrith Community Dialysis Centre - Nepean Hospital
Shellharbour - Wollongong Hospital
Shoalhaven Satellite (Nowra) - Wollongong Hospital
Singleton Satellite - Hunter New England Health

Sutherland Hospital - St George Hospital
Sydney Dialysis Centre - New South Wales
Taree Community Dialysis - Hunter New England Health
Wagga Wagga Base Hospital

Wansey Satellite - Hunter New England Health
Wellington Hospital - New South Wales
Wollongong Satellite - Wollongong Hospital - New South Wales

AUSTRALIAN CAPITAL TERRITORY (ACT)

Canberra Community Satellite Northside Dialysis Clinic (Fresenius)

VICTORIA

Angliss Hospital Ararat Hospital

Ararat Hospital
Austin Training Satellite - Austin Health
Bairnsdale Regional Health
Ballarat Health Service
Bendigo Hospital
Box Hill Satellite - Eastern Health Integrated Renal Services
Broadmeadows Satellite
Brunswick Satellite

Casey Hospital - Berwick Casterton Hospital Caulfield General Medical Centre

Caulfield General Medical Centre
Coburg Satellite
Cohuna Hospital
Colac Hospital
Craigieburn Satellite
Cranbourne Satellite
Dandenong Satellite
Daylesford Hospital
Diamond Valley Dialysis Clinic (Diaverum)
Donald Hospital
Echuca Hospital
Edenbone Hospital

Edenhope Hospital Epping Dialysis Unit Frankston Satellite Goulburn Valley Hospital Hamilton Hospital Hastings Hospital Heidelberg Hospital - Austin Health

VICTORIA (CONTINUED)

Horsham Satellite Kyneton Hospital Latrobe Regional Satellite Mansfield District Hospital Maroondah Satellite Maryborough Hospital Melton Hospital Mildura Hospital Moorabbin Satellite Myrtleford Hospital Newcomb Satellite
Nhill Hospital Satellite

Northern Hospital Satellite - Royal Melbourne North East Kidney Service - Austin Health North Melbourne Dialysis Clinic (Diaverum) Orbost Hospital Peter James Centre

Portland District Health Robinvale Hospital Rosebud Hospital Sale Hospital

Sale Hospital
Sandringham Satellite
Seymour Hospital
South Geelong Satellite - Geelong Hospital
St. George's Hospital
Sunshine Satellite Centre - Western Health
Swan Hill Hospital
Wannambool Hospital
Warnnambool Hospital Werribee Mercy Hospital
Western Gippsland Hospital
Williamstown Satellite
Wodonga Regional Health Service Wonthaggi Hospital Yarawonga District Hospital Yarram Hospital

TASMANIA

North West Renal Unit, Burnie - Launceston Hospital

SOUTH AUSTRALIA

Berri Satellite Ceduna Hospital Clare Satellite

Hampstead Rehabilitation Satellite

Hartley Private Hospital (Fresenius)
Lyell McEwin Satellite
Millicent Hospital
Modbury Satellite (Fresenius)
Mount Gambier Satellite Murray Bridge Hospital Noarlunga Satellite Payneham Satellite (Baxter) Port Augusta Hospital Port Lincoln Satellite Centre Wayville Satellite Centre Whyalla Satellite Centre

Whyalla Satellite Centre
NORTHERN TERRITORY
Flynn Drive Satellite - Alice Springs Hospital
Katherine Dialysis Unit - Royal Darwin Hospital
Nightcliff Community Centre - Royal Darwin Hospital
Palmerston Satellite - Royal Darwin Hospital
Tennant Creek Hospital - Alice Springs Hospital
Tiwi Dialysis Centre - Royal Darwin Hospital

WESTERN AUSTRALIA

Albany - John Hortin Dialysis Unit Armadale Satellite Bunbury Satellite Busselton Satellite

Cannington Dialysis Clinic (Diaverum)
Derby Satellite

Geraldton Hospital Joondalup Satellite Kalgoorlie Dialysis Unit

Kimberley Dialysis Unit Kimberley Dialysis Centre - Royal Perth Hospital Melville Satellite Midland Private Dialysis Centre (Baxter) Peel Health Campus - Mandurah

Port Hedland Dialysis Unit (Pilbara)- Royal Perth Hospital

Rockingham Satellite Spearwood Satellite Stirling Dialysis Clinic (Diaverum)

NEW **Z**EALAND

Auckland Home Training Unit
Bay of Islands Hospital - Whangarei Hospital
Carrington Satellite - Auckland City Hospital
Grafton Training Unit - Auckland City Hospital Greenlane Hospital - Auckland City Hospital Manukau Satellite - Middlemore Hospital Middlemore Satellite - Middlemore Hospital

Nephrocare - Auckland


Nelson Hospital

Porirua Community Dialysis - Wellington Hospital Rotarua Hospital - Waikato Hospital Tauranga Hospital - Waikato Hospital Waitakere Satellite - Auckland City Hospital



Publications in peer-reviewed journals based substantially on data from ANZDATA and released during the period of data covered by this report (2010) and during 2011 are listed below.

- 1 Clayton P, McDonald S, Chadban S. Steroids and Recurrent IgA Nephropathy After Kidney Transplantation. Am J Transplant. 2011; 11: 1645-49.
- Dobler CC, McDonald SP, Marks GB. Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study. PLoS ONE. 2011; 6: e29563.
- Lim WH, Boudville N, McDonald SP, Gorham G, Johnson DW, Jose M. Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. *Nephrol Dial Transplant*. 2011; **26**: 3366-72.
- 4 Lim WH, Chadban S, Campbell S, Cohney S, Russ G, McDonald S. A review of utility-based allocation strategies to maximize graft years of deceased donor kidneys. *Nephrology*. 2011; **16**: 368-76.
- Lindsay RM, Suri RS, Moist LM, Garg AX, Cuerden M, Langford S, et al. International quotidian dialysis registry: Annual report 2010. *Hemodial Int*. 2011.
- Roberts MA, Polkinghorne KR, McDonald SP, Ierino FL. Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. *Am J Kidney Dis.* 2011; **58**: 64-72.
- 7 Siva B, McDonald SP, Hawley CM, Rosman JB, Brown FG, Wiggins KJ, et al. End-stage kidney disease due to scleroderma -- outcomes in 127 consecutive ANZDATA registry cases. *Nephrology Dialysis Transplantation*. 2011; **26**: 3165-71.
- Thirugnanasambathan T, Hawley CM, Badve SV, McDonald SP, Brown FG, Boudville N, et al. Repeated Peritoneal Dialysis-Associated Peritonitis: A Multicenter Registry Study. Am J Kidney Dis. 2012; **59**: 84-91.
- 9 Burke M, Hawley CM, Badve SV, McDonald SP, Brown FG, Boudville N, et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. *Am J Kidney Dis*. 2011; **58**: 429-36.
- Marshall MR, Hawley CM, Kerr PG, Polkinghorne KR, Marshall RJ, Agar JW, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. *Am J Kidney Dis*. 2011; **58**: 782-93.
- Bose B, McDonald SP, Hawley CM, Brown FG, Badve SV, Wiggins KJ, et al. Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clin J Am Soc Nephrol. 2011; 6: 2657-61.
- 12 Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, *et al.* Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. *Nephrol Dial Transplant.* 2011; **In Press**.
- Ghali JR, Bannister KM, Brown FG, Rosman JB, Wiggins KJ, Johnson DW, et al. Microbiology and Outcomes of Peritonitis in Australian Peritoneal Dialysis Patients. Perit Dial Int. 2011; 31: 651-62.
- Gray NA, Dent H, McDonald SP. Renal replacement therapy in rural and urban Australia. *Nephrol Dial Transplant.* 2012; **27**: 2069-76.




MBER OF

CLONAL



INSTRUCTIONS FOR DIALYSIS AND TRANSPLANTATION SURVEY COMPILATION PLEASE READ THE EXPLANATORY NOTES BEFORE COMMENCING TO FILL IN THE FORMS Please complete the form using neat capitals

| | | B | | |
|--|--|---|---|--|
| 5 - RACIAL ORIGIN | PRIMARY RENAL DISEASE cont | INFECTION | UREA REDUCTION RATIO % | S4 - CAUSE OF GRAFT FAIL |
| 1 Calicasold 2 Australiae Abortoine | D18 Light chain nephropatry (benign) D19 Librium bxicity | Pleage enter code for nature of infective organism, after the | Pre-dialytic urea - root dialytic urea. (x 100 = URR%) | REJECTION |
| 3 Chinese | 020 Rost partum nephropathy 021 Sartoldosis | eg Staph, CAN, Candida, etc | Pre dialytic urea: | 10 Hyperacute rejection (within 48 hours of 20 Acute rejection at anytime, causing graft |
| 5 And 51 Doos lander | 031 Posterior uretiral valves 032 Periv-uretenc junction obstruction | egi. 321 Lung Infection – bacterial (staph) 322 Lung infection – vinal (CMF) | Blood should be aroun from the britishs' needle | 40 Chronic allograft nephropathy (slow prog- rensistancion, not due to recurrent onge- |
| | 033 Obstructed megalineter 034 Neuropathic bladder | | Poct dialysis urea: | or scule rejection) |
| 65 Tomes Strak Islander | 035 Non-obstructed dilated bladder and ureters (medacystitle – medalureter) | Umany tract | Blood is again drawn from the batteral needle and this should occur within 20 seconds after cessation of the blood number. | 50 Renal artery stenosis |
| Things of the state of the stat | 036 Spina bilida or myelomeningocoele 037 Bladder netk obstruction (Incl. prostolomegaly) | 34. Wound 4 Promises 35 Shunk 5 Other | (alternatively the bump can be turned down to 50 minute; - this is to avoid problems with recirculation. | 51 Renal artery thrombosis 52 Renal ven thrombosis |
| 9 Malay | 039 Coher lower unhany tract abnormances (with secondary reflux) (specify) | | 32 - ACCESS IN USE | 54 Rena Vesse haemomage (primary) 54 Rena Vesse haemomage (secondary) |
| | Out Unreferic obstructive nephropatry Out Obstructive nephropatry | Control for Utonin bottl 37. Septicemia - Sie unimom (specify organism) 38. Hum for this becelled imagin in the set | Type at First HD Heave blank it initial renal replacement prestructs was not been oblaves. | 56 Embous - thrombo 56 Embous - cholestero |
| DD. Patient objects to answering question | TOTAL OF THE PARTY OF THE PARTY OF THE | 39 Other site (speoffy) | Type at Laci HD - enterfor all patients on haemodalysis at | TECHNICAL |
| 6 - PRIMARY BENAL DISEASE | Frem CAPD to APD | SOCIAL 40 Withdraws for psycho-socia reasons | any time during the survey. Enter the procedure closest to the end of survey, change to PD, transplantation, or death. | 60 Non-visible kigney (due to pre-transplant 61 Contical nectods Post transplant (not du |
| Recurse of ANCA (Anti Neutrophii Cytopisemio Antibody) | From APD to CAPD | 41 Patient refused further treatment (appendig reacon) 42 Suicide | 33 - PET TEST Required Once Only per collects | 10 United and bladder problems |
| tect in accordation with glomerulonephritic chould be enfored in box marked OTHER. | From any form of PD to HD | 43. Therapy ceased for any other reason (appeally reason). 44. Accretional death (country). | Standard Pertitional Dialytils Equilibration Test | 82 Mesangiocapilary GN with subendotheli |
| 400 Presumed GN, the undefined histologically incibiosoci | From HD to any form of PD | | performed 1-5 months after initiation of PD (2.5% 2 little exchanges) | 83 Mesanglocapitary GN with Intramentoral (dence deposit disease) |
| 110 Focal scienceing GN (including tyglinosis) | 11 Acute perturits | 47 Withdrawal for peripheral vascular comorbid conditions | Provide dialyticiplatma preatinine at 4 hours | 84 Facal scientising GN (including hysinodia 85 Membranous GN |
| scendis | 15 Turne) extrate infection 15 Diverticuits | | Andreas and the contract of the contract of | 86 Mesangla profferable GN (ligh positive) 87 Cookbast light conduction |
| 112 occurrany total screening un 121 Mesanglocapitary GN WITh subendothelia | 20 inadequate courte cearance 21 inadequate fluid ultrafitration | MISCRITANEOUS | Secretary from a 24 hour collection of PD artured | 88 Intra and extra capillary GN with extensive |
| Oggostic (double contour) (22 Mesanglocapilary GN with Intramembranous | 22 Excessive field utraffordion 27 Applominal absorbes | SO HEDST CALLE LEGGENTY | and urline | 89 Other (speothy) |
| deposits (dense deposit disease) 130 Membranous GN | 30 Dispate leaf | 51 Litramia caused by graff failure 52 Baccontin | NOTE: Dialysate Creatinine Clearance and R2V both refer to daystic clearances ONLY (NOT the total of dialysis and renal | DRUG THERAPY |
| 140 Extra and intra capitary GN textensive conscents - childrally congressive) | 32 Haemoperibreum | 53 Bone marrow depression | Ceanness Assessment of CARAMAC - DIAN CORTE CAN C | withdrawal of steroid and or immunosup |
| 151 Metangial proliferative (IgA+ positive) | 35 HETE | St. Calmount | | 92 Rejection following list reduction due to |
| 53 Mesangia professive high registre) | 36 Abdominal path 40 Abdominal surgery | 56 Malignant disease 57 Perforation of abdominal viscus | S8 WEEKLYKKW - DIALYSATE ONLY Range 01-50 | 83 Reedon following life reduction due to the control of the contr |
| (60) Focal and segments professive GN (including focal necrotising) | | petite ulcer, diverticulum, appendix. | 40 RESIDUAL RENAL FUNCTION | D OTHER SPORTS |
| (TD. Advanced GN (unidassified - end stage) (80 GN with systemic disease (speody) | 43 Multiple adherions | 59 Other (specify) | (Creatinine Clearance) Lines / week / 1.73 m² Body Surface Area. | 01 Donor malgnancy 02 Materiancy invading profit |
| 181 Goodpapure's syndrome with their gG and und haemorthage | 45 Hemshrib | (specify organisms involved | 49 - SOURCE OF DONOR KIDNEY | OS BK virus deprespatity |
| 182 Profestive DN with linear log no lung haemonthage 183 SLE | 47 Cardiovascular Instability | 62. Sciendaling pertonitis | 2 Sister If wh. record 6 or 7 | 55 - MONOCLONAL / POLYC |
| 184 Henoth-Schonlein purpura | 48 Designating - poor access to dialysis services 49 Vancular access problems | 19 - TYPE OF DIALYSIS | 3 Brother (If Min. record 5 or 7) 4 Mother | THERAPY |
| 186 Microscopic Polyanteritar | 50 Patient preference 51 Unable to manage self-care | Haemodaysis – plate dalysers Haemodaysis – holow fore dalysers | 5 Father 6 Monazgotic (identical) twin | Record in order of administration, each sepa such drugs; a second course of the same dr |
| 190 GN other (speakly) | 60 Recovery of renal function 78 Transplantation | (5 Haemofftration 16 Haemodafftration | 7 Dizygotic Inon-lentical twin 8 Other related from donor (specify) | separately recorded. |
| 19) Familia GN (specify Aportis : yes or no) 200 Anapesic neptropathy | 80 Death 81 Transfer outside Australia or New Zealand | 19 G.V.V.V.D distance Care Units 20 Performs - Bass to pricer | 9 Son | Complete the requested details regarding, to drug, number of dodes given, and reason for |
| 300 Renal vapouar disease due to maignant hypertension (NO primary renal disease) | 82 Other surpery | 21 Pertoneal - continuous ambulatory (CAPD) | II Hutband | according to the following codes. |
| 301 Renal vascular doesse – type unspecified 302 Renal vascular doesse – due to hypertension | 85 Por nutrition | 23 Periones - stemitter (per IPD) | 13 Course | |
| (hephrospeross) (NO primary renal disease) 303. Afreroembolic disease (cholestero) emboli) | 90 Planned transfer after acute PD start | Angella, Island Ballanda | SO TOTAL ISCHARMIA (HOLIBS) | 4 OKT3 Rec |
| | 59 Other (specify) | At end of survey, transplantation or death. | From time of donor renal artery interruption or addition | |
| | | 21 - UNCORRECTED CALCIUM | clamp, until time of release of renal artery in the recipient (clamp off). | 8 Polydona and Ticel |
| | 16 - CAUSE OF DEATH | Not corrected for albumin | S1 - IMMEDIATE FUNCTION | REASON FOR USE |
| | CARDIAC | Money, predaying, at end of survey, transportation of death. | 1 Sportaneous fall in secreptifier by 10% with 24 hours 2 Sportaneous fall in secreptifier by 10%, first | Treatment to scale rejection |
| 801 Disbetes - Type 1 (fraulin dependent) (Luvenille onset). 802 Disbetes - Type 2 (non-insulin requing) | 18 Myocarda lactaema (presumed) | 22 - PHOSPHATE | recorded between 25-72 hours 3. Poor immediate function No sportaneous fail in | a Other (specify) |
| | 12 Furnionary bedema | Micheel, predaytis, a did of survey, transpariation of death. | se creatinine within 72 hours, but no daysts needed 4. No immediate function No sportameous fail (> 10%) | 56 - TOTAL DAILY DRUG DO |
| 001 Uncertain disgricus 002 Lead nephropativ | | 23 - HAEMOGLOBIN | in se.creatione, days a required within 72 hours | Enter the total daily doze for each drug when |
| 003 Cadmium bricity 004 Renal Libertulosis | 16 Cardac arrest – cause uncertain 17 Other causes of cardac fallure (speeify) | Midweek, prediatysis, at end of survey, transpisitistion or death. | 52 - DISEASE IN GRAFT Histologically proven | marked OTHER. |
| 005 Amyloid disease 006 Nemolytic unsemic syndrome | | 31 - URR or KtV Please enformethod used | Please enter Date first proven (e.g. Graff Blopsy) | Only those drugs bitten at the listed intervals entered; where necessary provide the dose in |
| | 21 Pumorary embous 22 Cerebroagular account | A Ures Reduction Ratio % (URR%) | V = Disease recurrence | closest day preceding the requested time int. The initial data date for zero months is the |
| use congernal resal appopasa and goodsale 010 Loss of shore kichey (appoint) - e.g. traums, purpery) 011 Medurates | 23 Castrontestral faemontage 24 Haemontage from diaysis access site | B NEW ISY BIOSTATI | primay tens process an update in grant of care. 0 - De novo glomentomoshatis - onmay rens glosese known and occupe came. | meintenance doce. DO NOT enter the Intra doces administered at or shortly after transp |
| D12 Chalopis D13 Chalopis | 25 Haemonthage from transplant artery 26 Aortic aneurysm – rightine | E NAV (other method – speody) | G = Glomestionephrits in graft - Indian rens disease unknown or not blocated | (2007) |
| 014 Baltan rephropathy 015 Renal cel carchoma (854N/TZ) | 27 Haemontage from elsewhere (speoffy) 28 Bowel infantion | NEW (for HD patients) Range 0.5 - 2.2 | in cases of promerulonephrits, where histological confirmation | |
| DNE Transitional cell carchioma of umany tractional of the Personnelment of the procedure of the personnel o | | | of recurrence may be uncertain, enter as u | |
| | | | | |
| | | | | |



Phil Clayton Stephen McDonald Kylie Hurst





KEY SUMMARY POINTS

AUSTRALIA

- There were 18,999 people (850 per million population) receiving renal replacement therapy (RRT) at 31st December 2010. Of these, 8,409 (376 per million) had a functioning kidney transplant and 10,590 (474 per million) were receiving dialysis treatment.
- 2,257 people commenced RRT in Australia in 2010 (101 per million per year). The incidence rate varied from 279
 per million population per year in the Northern Territory to 92 per million per year in the Australian Capital
 Territory (ACT).
- The mean age at commencement was 60.7 years, the median 62.9 years and the age range < 1 months 93.2 years.
- 35% of new patients had diabetic nephropathy attributed as their cause of end stage renal failure, 22% had glomerulonephritis and 14% hypertension.
- The mortality rate per 100 patient years was 13.42 for dialysis dependent patients and 1.11 for those with a functioning kidney transplant.
- Of the 1,401 deaths among dialysis dependent patients in 2010, 35% were due to withdrawal from treatment, 43% were due to cardiovascular causes, 11% to infection and 6% from malignancy.
- Of the 160 deaths among patients with kidney transplants, 32% were due to malignancy, 23% to cardiovascular causes and 23% to infection.
- There has been a 2% increase in the total number of prevalent dialysis patients from 10,425 in December 2009 to 10,590 in December 2010.
- There were 846 kidney transplant operations performed in 2010, (a transplant rate of 38 per million population). This was the highest number ever of transplants performed.
- Of these, 35% (296 grafts; 177 related and 119 non related) were from living donors, compared with 42% (327grafts; 185 related and 142 non related) in 2009. 35% of primary live donor operations were performed without the recipient receiving prior dialysis therapy ("pre-emptive" transplants).
- For primary deceased donor grafts performed in 2009-2010, the 12 month patient and graft survival rates were 98% and 95% respectively.
- The five year primary deceased donor recipient and graft survival for operations performed in Australia and new Zealand 2005-2009 were 90% and 82% respectively.
- In 2010, 1208 patients (87%) of Aboriginal/TSI ethnicity were dialysis dependent and 177 patients (13%) had a functioning transplant. There were 198 patients that commenced renal replacement therapy.
- The proportion of haemodialysis patients with a haemoglobin value >120 g/l has fallen consistently over the past three years (presumably in response to evidence about the adverse effects of higher Hgb targets in some groups).
- There has been a stabilisation in the proportion of people with serum phosphate >1.8 mmol/L over the last few years.
- Among people receiving haemodialysis as their initial treatment modality, and referred to a nephrologist more than
 three months prior to starting dialysis, only 51% of people had a usable permanent access (AV fistula or graft) at the
 time of initial haemodialysis.

KEY SUMMARY POINTS

NEW ZEALAND

- There were 3,793 people (868 per million) receiving renal replacement therapy (RRT) at 31st December 2010.
 Of these, 1,415 (324 per million) had a functioning kidney transplant, and 2,378 (544 per million) were receiving dialysis treatment.
- 503 people (115 per million per year) commenced RRT in New Zealand in 2010.
- The mean age at commencement was 58.3 years, the median age 60.3 years and the age range 9.2 months 86.5 years.
- Diabetic nephropathy accounted for 51% of new patients, glomerulonephritis 22% and hypertension 12%.
- Of the incident diabetic patients, 113 patients (44%) were Maori, 73 patients (29%) were Pacific People, 49 patients (19%) were Caucasoid and 21 patients (8%) were of other ethnicity.
- Of patients < 60 years of age, 29% were on the active kidney transplantation waiting list at 31st December 2010. 21% of Maoris, 16% of Pacific People and 13% of Asians < 65 years of age were on the transplant waiting list.
- The mortality rate per 100 patient years was 13.68 for dialysis dependent patients and 1.36 for those with a functioning kidney transplant.
- Of the 319 deaths among dialysis dependent patients in 2010, 55% were due to cardiovascular causes, 21% to withdrawal from treatment, 17% to infection and 3% from malignancy.
- Of the 34 deaths among patients with a kidney transplant, 32% were due to malignancy,32% to cardiovascular causes and 12% due to infection.
- The number of patients who were dialysis dependent at 31st December 2010 (2,378) was an increase of 4% (2,280 patients) the previous year. 53% of all dialysis dependent patients were receiving home dialysis, of whom 66.1% were having peritoneal dialysis.
- There were 110 kidney transplant operations performed in 2010, a rate of 25 per million population.
- The percentage of live donors in 2010 was 55% (60 grafts),
- For primary deceased donor grafts performed in 2009-2010, the 12 month patient and graft survival rates were 98% and 96% respectively.
- The five year primary deceased donor recipient and graft survival for operations performed in Australia and New Zealand 2005-2009 were 90% and 82% respectively.
- Among people receiving haemodialysis as their initial treatment modality, and referred to a nephrologist more than
 three months prior to starting dialysis, only 32% of people had a usable permanent access (AV fistula or graft) at
 the time of first treatment.